

India gets another CyberKnife cancer center

21 November 2012 | News | By BioSpectrum Bureau

India gets CyberKnife technology for cancer



Singapore: India's specialty institutes Medanta (Medicity Cancer Institute) and the Roentgen-BLK super speciality hospital have acquired CyberKnife VSI System, the premier solution for full-body radiosurgery. The CyberKnife technology is developed by US-based Accuray, a premier company in the domain of radiation oncology.

Medanta and Roentgen-BLK Radiation Oncology Center can now use the CyberKnife System to expand its patient base. Patients on the other hand can now benefit from CyberKnife radiosurgery and stereotactic body radiation therapy (SBRT) in the region.

"The CyberKnife System is increasingly being used as an alternative to conventional radiation therapy in situations where its targeting accuracy allows a shorter and more intense course of radiation, including radiosurgery for brain tumors. We look forward to witnessing the benefits that the system offers, including real-time tracking with automatic correction of tumors that move throughout the body," said Dr Naresh Trehan, CMD, Medanta.

"Using the CyberKnife System allows our radiation oncologists to provide the most up-to-date technology available to accurately target tumors, deliver treatments with pinpoint accuracy and ensure that tumors get the most effective ablative dose while healthy tissues and critical structures are spared," said Dr Praneet Kumar, CEO, Roentgen-BLK Radiation Oncology Center.

The CyberKnife System provides fractionated high precision radiation therapy with robotic intensity-modulated radiotherapy (IMRT) that can be delivered anywhere in the body, including intracranial, head and neck, spine, lung, liver and prostate. The enhanced spectrum of treatment options allows for more customized treatment plans based on patient-specific situations and conditions, such as patients requiring re-irradiation of previously treated area, or patients requiring partial breast irradiation.